Biotechnology Pharmaceutical Company Selects NewCardio's QTinno for Thorough QT Trial
Fully Automated ECG Analysis, Empowered by QTinno, to be Delivered through Integrated Clinical Trial Services Provided by Top 3 CRO
PRINCETON, N.J., Jan. 11, 2012 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, announced today that a biotechnology pharmaceutical company, which is focused on discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS), has selected QTinno®, NewCardio's automated cardiac safety solution, for an upcoming Thorough QT trial. Fully automated ECG analysis, empowered by QTinno, will be delivered by the ECG core lab of a top 3 Clinical Research Organization (CRO) under the terms of an existing Master Services Agreement with NewCardio.
The current study timeline anticipates initiating the study in January, with completion in the April timeframe. QTinno was selected, and specifically written into the protocol by the drug development sponsor, based on its proven ability to enable the CRO to deliver high-quality results in a much more timely and cost effective manner than the current core ECG lab methodologies. It is anticipated that the study will generate approximately $250,000 in revenue for NewCardio.
Greg Sadowski, NewCardio's Chief Operating Officer, commented, "We are excited to participate in this TQT trial for an emerging biotech with our CRO partner. QTinno's selection for this study, based on the performance in prior studies, provides clear evidence of the pharmaceutical company's confidence, not only in the accuracy and precision of QTinno's fully automated ECG analysis, but also in the FDA's willingness to accept drug safety data from properly validated technology such as QTinno."
